INSMINSMED Inc

Nasdaq insmed.com


$ 76.66 $ 0.46 (0.6 %)    

Wednesday, 21-Aug-2024 15:16:43 EDT
QQQ $ 481.63 $ 0.51 (0.11 %)
DIA $ 409.07 $ -0.16 (-0.04 %)
SPY $ 560.02 $ 0.09 (0.02 %)
TLT $ 98.92 $ 0.24 (0.24 %)
GLD $ 232.26 $ 0.60 (0.26 %)
$ 76.19
$ 76.20
$ 76.58 x 100
$ 77.50 x 100
$ 75.64 - $ 77.17
$ 21.21 - $ 78.87
2,216,387
na
11.79B
$ 1.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-22-2024 12-31-2023 10-K
4 10-26-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 02-23-2023 12-31-2022 10-K
8 10-27-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-17-2022 12-31-2021 10-K
12 10-28-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 10-29-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 04-30-2020 03-31-2020 10-Q
19 02-25-2020 12-31-2019 10-K
20 10-30-2019 09-30-2019 10-Q
21 08-01-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 02-22-2019 12-31-2018 10-K
24 10-30-2018 09-30-2018 10-Q
25 08-02-2018 06-30-2018 10-Q
26 05-02-2018 03-31-2018 10-Q
27 02-23-2018 12-31-2017 10-K
28 11-02-2017 09-30-2017 10-Q
29 08-03-2017 06-30-2017 10-Q
30 05-03-2017 03-31-2017 10-Q
31 02-23-2017 12-31-2016 10-K
32 11-03-2016 09-30-2016 10-Q
33 08-04-2016 06-30-2016 10-Q
34 05-05-2016 03-31-2016 10-Q
35 02-25-2016 12-31-2015 10-K
36 11-06-2015 09-30-2015 10-Q
37 08-06-2015 06-30-2015 10-Q
38 05-07-2015 03-31-2015 10-Q
39 02-27-2015 12-31-2014 10-K
40 11-06-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 truist-securities-maintains-buy-on-insmed-lowers-price-target-to-85

Truist Securities analyst Nicole Germino maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $88 to $85.

 hc-wainwright--co-reiterates-buy-on-insmed-maintains-90-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Insmed (NASDAQ:INSM) with a Buy and maintains $90 price target.

 td-cowen-maintains-buy-on-insmed-raises-price-target-to-98

TD Cowen analyst Ritu Baral maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $75 to $98.

 ubs-maintains-buy-on-insmed-raises-price-target-to-84

UBS analyst Trung Huynh maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $78 to $84.

 stifel-maintains-buy-on-insmed-raises-price-target-to-88

Stifel analyst Stephen Willey maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $74 to $88.

 rivian-automotive--baidu-are-among-top-11-large-cap-stocks-that-shined-the-brightest-last-week-july-7-july-13-are-the-others-in-your-portfolio

Top performers in last week: RIVN (+21.37%), EMPH (+21.15%), DHI (+12.53%), BLD (+12.15%), BIDU (+11.80%), GLW (+11.54%), INSM ...

 morgan-stanley-maintains-overweight-on-insmed-raises-price-target-to-85

Morgan Stanley analyst Matthew Harrison maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $6...

 goldman-sachs-maintains-buy-on-insmed-raises-price-target-to-102

Goldman Sachs analyst Andrea Tan maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $74 to $102.

 guggenheim-maintains-buy-on-insmed-raises-price-target-to-95

Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $70 to $95.

 hc-wainwright--co-maintains-buy-on-insmed-raises-price-target-to-90

HC Wainwright & Co. analyst Andrew Fein maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $70 t...

 b-of-a-securities-maintains-buy-on-insmed-maintains-83-price-target

B of A Securities analyst Jason Zemansky maintains Insmed (NASDAQ:INSM) with a Buy and maintains $83 price target.

 insmed-presents-additional-data-from-pivotal-aspen-study-of-brensocatib-in-patients-with-bronchiectasis-at-the-7th-world-bronchiectasis-conference

—New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Brensocatib 25 mg Versus Plac...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION